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REVIEW
Background: An emphasis on more aggressive lipid-lowering, particularly of low-density
lipoprotein cholesterol, to improve patient outcomes has led to an increased use of combination
lipid-lowering drugs. This strategy, while potentially beneficial, has triggered concerns
regarding fears of adverse effects, harmful drug interactions, and patient nonadherence.
Objective: To present key data regarding combination lipid-altering therapy including use,
rationale, major trials, benefits, potential adverse effects, compliance issues, and limitations.
Method: Literature was obtained from MEDLINE (1966 – June 2005) and references from
selected articles.
Results: A substantial body of evidence from epidemiological data and clinical trials indicates
that aggressive lipid modification, especially low-density lipoprotein reduction, is associated
with reduced cardiovascular events. Numerous studies utilizing various combinations of
cholesterol-lowering agents including statin/fibrate, statin/niacin, statin/bile acid resin, and
statin/ezetimibe have demonstrated significant changes in the lipid profile with acceptable
safety. Long-term trials of combination therapy evaluating clinical outcomes or surrogate
markers of cardiovascular disease, while limited, are promising.
Conclusion: Combining lipid-altering agents results in additional improvements in
lipoproteins and has the potential to further reduce cardiovascular events beyond that of
monotherapy.
Keywords: combination therapy, coronary heart disease, hypercholesterolemia, lipid-lowering,
low-density lipoprotein, statins
Introduction
Coronary heart disease (CHD) continues to be a leading cause of morbidity and
mortality in the United States, affecting an estimated 13 million individuals or
approximately 7% of the total population (AHA 2005). One of every five deaths was
attributed to CHD in 2002. Estimated total costs for CHD in 2005 exceeded
$142 billion. Elevated low-density lipoprotein cholesterol (LDL-C) is a major
modifiable risk factor for CHD. The National Cholesterol Education Program (NCEP)
Adult Treatment Panel’s third report (ATP-III) focuses on evidence from clinical
trials demonstrating the importance of LDL-C reduction to reduce the risk of CHD
(ATP-III 2002). The initial ATP-III report defined target goals for LDL-C based on
CHD risk. Lowering LDL-C to less than 100 mg/dL was recommended for those
with known CHD or CHD risk equivalents such as diabetes. Since the release of
ATP-III in 2001, additional clinical trials have suggested that further reduction of
LDL-C to lower targets may provide additional risk reduction. Based on this new
evidence, NCEP published the ATP-III Update in 2004, proposing modifications to
the guidelines (Grundy et al 2004). For individuals considered to be at very high-
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aggressive lipid-lowering. Additionally, the document
suggested a minimum LDL-C reduction of 30%–40% for
those considered to be at moderate to very high risk for
CHD, a goal that is not always achievable with monotherapy
(Grundy et al 2004). A recent study of patients with
dyslipidemia who were risk-stratified based on NCEP
guidelines found that less than 60% of patients with CHD
or CHD risk equivalents achieved NCEP goals for LDL-C
with monotherapy (Davidson et al 2005). To overcome the
limited efficacy of single agents and avoid increased toxicity,
which is often dose-related, the concept of combination drug
therapy has emerged as a potential strategy for the
management of dyslipidemia (Worz and Bottorff 2003;
Davidson and Toth 2004). However, the use of combined
lipid-altering agents is not without safety concerns,
especially with certain combinations that warrant close
monitoring and patient education. Two combination drug
products have received Food and Drug Administration
(FDA) approval: Advicor
® (lovastatin and extended-release
[ER] niacin, Kos Pharmaceuticals, Miami, FL, USA) and
Vytorin
® (ezetimibe and simvastatin, Merck/Schering-
Plough Pharmaceuticals, New Jersey, USA).
The benefits of combination drug therapy are well
established for various other cardiovascular risk factors, with
hypertension representing perhaps the clearest example.
Monotherapy has been shown to be ineffective in
approximately 50% of unselected hypertension patients and
the majority of those with more advanced stages of
hypertension (Materson et al 1993). The Joint National
Committee on Prevention, Detection, Evaluation, and
Treatment of High Blood Pressure recommends combination
therapy as an option for stage I hypertension when
monotherapy is inadequate and also for most stage 2 patients
(Chobanian et al 2003).
Similarly, combination therapy has been shown to be
advantageous in type 2 diabetes mellitus (DM) resulting in
better glycemic control and fewer complications (Bell and
Ovalle 2004; Strowig et al 2004).
For patients with dyslipidemia, hesitancy to use
combination therapy has centered on concerns that the risk
of adverse effects, particularly rhabdomyolysis (Ballantyne,
Corsini, et al 2003; Graham et al 2004) could be increased.
Theoretically, by combining drugs that target different
components of lipid metabolism, greater lipid-lowering
can be achieved while still limiting toxicity. This article
will review the current literature on combined drug
treatment for LDL-C lowering and discuss current implica-
tions for practice.
Pharmacologic agents
Potential benefits and risks with combination lipid-altering
therapy stem largely from the pharmacology of individual
drugs. We will briefly review individual agents that may be
considered for combination regimens.
Niacin (nicotinic acid)
Niacin or vitamin B3 has been utilized in high doses as a
lipid-modifying agent for 50 years (Altschul et al 1955).
This agent favorably alters all major lipoproteins (ie, high-
density lipoprotein cholesterol (HDL-C), LDL-C, and
triglycerides) and is one of the only cholesterol-lowering
drugs to significantly reduce lipoprotein (a) (Lp[a]). Niacin
is available as a nutritional supplement in numerous
formulations (ie, crystalline immediate-release [IR] and
sustained-release [SR]) as well as by prescription as ER
(Niaspan®, Kos Pharmaceuticals, Miami, FL, USA). Despite
the beneficial impact of niacin on the lipid profile, use is
often limited by intolerable side effects.
Although the pharmacology of niacin is not fully
understood, the primary effect is inhibition of the synthesis
and secretion of hepatic very low-density lipoprotein
cholesterol (VLDL-C) which reduces triglycerides and
LDL-C (Grundy et al 1981; Knopp et al 1985). Additionally,
niacin is the best available agent for raising HDL-C (Knopp
et al 1985). This effect is produced by slowing the catabolism
of the predominant HDL-C apolipoprotein (apoprotein A-1)
and reducing triglycerides (Shepherd et al 1979). Lastly,
niacin has demonstrated the capacity to cause a shift in the
size of LDL-C (Backes and Gibson 2005), converting the
more atherogenic small-dense LDL-C (sdLDL-C) particles
to the larger, more buoyant LDL-C.
In high doses, niacin can significantly alter HDL-C,
LDL-C, triglycerides, and Lp(a) in a dose-dependent
manner. While these lipoprotein effects vary with the
formulation utilized (ie, IR, SR, or ER), niacin typically
reduces LDL-C (5%–25%), triglycerides (20%–50%) and
Lp(a) (30%–39%) while increasing HDL-C (15%–35%)
(ATP-III 2002). The IR formulation is generally more
effective at raising HDL-C and reducing triglycerides
compared with the SR formulation (McKenney 2004).
Niacin dosing varies with the product used, but doses of up
to 4000 mg daily of the IR and 2000 mg daily of the ER
have been studied.
The major limitation of niacin is its side-effect profile.
The predominant adverse effect is a prostaglandin-mediated
cutaneous flushing that results in discontinuation rates ofVascular Health and Risk Management 2005:1(4) 319
Combination lipid-lowering therapy
5%–50% (Berge 1961; McKenney et al 1994; Guyton et al
1998) depending on the dose and formulation. Flushing can
be lessened by aspirin administration (325 mg) 30 minutes
prior to the niacin dose or by utilizing a SR or ER product.
The SR products cause less flushing, but are associated with
hepatotoxicity, especially at doses greater than 2000 mg per
day (Knopp et al 1985; McKenney et al 1994). The ER
niacin, Niaspan, which has intermediate absorption
characteristics compared with the IR and SR, was developed
to maintain lipid profile effects comparable to the IR while
causing flushing rates similar to the SR. Niacin has also
been associated with metabolic effects. Minor blood glucose
elevations (eg, 5%) are generally transient, however, some
patients may experience larger and more persistent increases
(Elam et al 2000). Typically doses < 1500 mg daily have
little effect on blood glucose (Elam et al 2000). Because
niacin competes with uric acid for renal elimination, mild
elevations in uric acid levels have been noted, and niacin
should be used with caution in those predisposed to gout.
Approximately 10%–30% of patients complain of
gastrointestinal (GI) symptoms (eg, nausea, abdominal pain)
with niacin; effects are more common with the SR
formulation and may be minimized with concomitant food
administration. However, those with a previous history of
peptic ulcer disease (PUD) should use niacin with caution,
and use is contraindicated with active PUD.
Bile acid sequestrants
Once considered first line agents for LDL-C reduction, bile
acid sequestrants (BAS) are now primarily utilized as
adjunctive therapy with newer agents (eg, statins) for
additional LDL-C reduction (PMSG 1993). This class
includes cholestyramine, colestipol (both approved in the
1970s), and colesevelam, which has been available since
2000. While the BAS are nonabsorbable resins that generally
possess a favorable safety profile, the older agents are
associated with drug interactions and numerous GI
complaints which limit use.
Bile acid sequestrants bind bile acids in the intestine, inter-
rupting enterohepatic recirculation, resulting in increased
fecal bile acid excretion. This stimulates LDL-C receptor
activity leading to an increase in uptake of LDL-C from the
systemic circulation, thereby reducing LDL-C levels
(Grundy et al 1971; Shepherd et al 1980). Because of this
reduction in LDL-C, hepatic cholesterol synthesis increases
secretion of VLDL-C with a consequential increase in
triglycerides and a limited effect on LDL-C levels. The
primary use for these agents is therefore LDL-C reduction.
Caution should be exercised for those with hypertriglyceri-
demia since these agents may worsen this disorder (Nestel
and Grundy 1976).
The expected reduction in LDL-C with BAS ranges from
15%–30%, with minimal increases in HDL-C and potential
increases in triglycerides among those with borderline or
elevated levels (ATP-III 2002). Higher doses are required
to achieve the upper range of LDL-C reduction, with the
strong possibility of nonadherence secondary to poor
palatability or side effects. Tolerability is one of the major
barriers to BAS use. Common side effects include bloating,
constipation, flatulence, epigastric fullness, and nausea
(Steiner et al 1991) with discontinuations rates exceeding
40% in clinical practice after one year (Andrade et al 1995).
Undesirable formulations represent another barrier.
Cholestyramine and colestipol are commonly prescribed as
powders or granules which may be mixed with juice to
improve palatability. Colesevelam is available in tablet form,
but requires six tablets daily to achieve maximum LDL-C
reduction. Lastly, the older BAS are associated with
numerous potential drug interactions. In addition to binding
bile acids, these BAS can sequester many commonly used
medications (eg, diuretics, digoxin, amiodarone, thyroxine,
acetaminophen, warfarin) (Steiner et al 1991). Concomitant
medications should be taken 1 hour before or 4 hours after
colestipol or cholestyramine. Because colesevelam has more
specificity for bile acids, drug interactions are less of a
concern (Aldridge and Ito 2001). Despite potential
disadvantages, BAS are still useful in clinical practice
particularly for patients with hepatic impairment, those
intolerant of statins, children, patients of childbearing
potential, and individuals requiring combination therapy to
achieve greater LDL-C reduction.
Fibric acid derivatives (fibrates)
While the effects of fibric acid derivatives on the lipid profile
primarily involve triglyceride reduction, significant increases
in HDL-C, varying effects on LDL-C levels, and improve-
ment in LDL-C particle size have also been observed
(Vakkilainen et al 2003). Commonly prescribed fibrates in
the United States are gemfibrozil and fenofibrate, and
bezafibrate and ciprofibrate are available in Europe. With
the rapid increase in patients with mixed dyslipidemia (eg,
DM and metabolic syndrome), fibrates may play a greater
role in the future for managing these lipid disorders.
The complex mechanism of action for fibrates involves
numerous steps in the metabolism of lipoproteins. These
agents primarily affect peroxisome proliferator-activatedVascular Health and Risk Management 2005:1(4) 320
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receptor-alpha (PPAR-α) and lipoprotein lipase (LPL).
Stimulation of LPL increases lipolysis, resulting in a
clearance of triglyceride-rich lipoproteins (Grundy and Vega
1987). The HDL-C increase produced by fibrates is due not
only to the reduction in triglycerides, but also secondary to
stimulation of PPAR-α and its effect on increasing synthesis
of apolipoprotein A particles (Fruchart et al 1998). Overall,
fibrates reduce triglycerides by up to 50%, increase
HDL-C 10%–20%, and provide modest reductions in total
cholesterol (TC) (ATP-III 2002). The effect of fibrates on
LDL-C is dependent on the type of dyslipidemia. Individuals
with elevated LDL-C (Type IIa) can experience a moderate
reduction in LDL-C levels (10%–20%) with fibrate therapy.
For patients with a mixed dyslipidemia pattern (Type IIb),
LDL-C effects are less predictable ranging from a modest
reduction to possible increased levels. Among those with
hypertriglyceridemia (Types IV and V) increases in LDL-C
are commonly noted (Knopp et al 1987). In addition, some
data suggest fenofibrate and bezafibrate possess better
LDL-C-lowering ability compared with gemfibrozil and
clofibrate (Blane et al 1986). Similar to niacin, fibrates have
been shown to normalize LDL-C composition, shifting from
sdLDL-C to the larger and more buoyant particles
(Vakkilainen et al 2003; Backes and Gibson 2005), which
appears to account for some of the antiatherogenic effects
of the class (Vakkilainen et al 2003).
Safety was a concern initially with this class due to the
World Health Organization (WHO) trial of clofibrate, which
found increased nonCHD mortality secondary to biliary tract
disease and cancer (CPI 1978). However, other long-term
studies with clofibrate (Anonymous 1975) and other fibrates
(Frick et al 1987; DAIS 2001) have not demonstrated an
increased risk. While fibrates are generally well tolerated,
potential side effects include GI complaints (eg, nausea,
abdominal pain), myalgias, increases in serum creatinine
levels (fenofibrate), cholelithiasis, and elevated transaminase
levels (Brown 1987; Hottelart et al 2002).
Hydroxymethylglutaryl-coenzyme A
reductase inhibitors (statins)
The statins have emerged as the cornerstone for LDL-C
lowering since the first agent, lovastatin, was approved in
1987. Five other statins are currently available, including
atorvastatin, fluvastatin, pravastatin, rosuvastatin, and
simvastatin. Cerivastatin was approved in 1997 and was
voluntarily withdrawn from the market in 2001 because of
a significantly higher rate of rhabdomyolysis compared with
the other statins (Staffa et al 2002). Nevertheless, the statins’
overall safety profile is excellent and numerous clinical trials
have indicated significant reductions in cardiovascular
events and total mortality.
Several mechanisms account for the pharmacological
effects of statins. The two primary modes of activity are
competitively inhibiting hydroxymethylglutaryl-coenzyme
A reductase (HMG-CoA reductase) (Davignon et al 1992),
a precursor to the formation of cholesterol, and upregulating
the LDL-C-receptor (Bilheimer et al 1983; Arad et al 1992;
Davignon et al 1992), secondary to the reduction in hepatic
cholesterol synthesis. In addition to marked LDL-C
reduction (20%–55%), statins also moderately reduce
triglycerides (8%–30%), via decreased hepatic cholesterol
synthesis, and produce minor increases in HDL-C (2%–10%)
(Jones et al 2003). It has also been demonstrated that statins
possess additional antiatherogenic activity beyond their
lipoprotein effects including improved endothelial function
(Asberg et al 2001), antiinflammatory properties (Backes
et al 2004), and antithrombotic effects (Rosenson and
Tangney 1998).
The statins are well tolerated by most patients with a
low incidence of adverse effects. The overall discontinuation
rate is reported to be < 4% (Hsu et al 1995) secondary to
such common adverse effects as myalgias, headache, and
mild GI complaints. The most concerning adverse events
are myopathy and elevation in transaminase levels, both of
which are dose-dependent (Ballantyne, Corsini, et al 2003).
The incidence of transaminase levels exceeding three times
the upper limit of normal occurs in < 3% of patients and
often improves with a reduction in dosage (Bradford et al
1991; Hsu et al 1995). Liver failure secondary to statins has
rarely been reported (Pederson and Tobert 1996). Although
the occurrence of nonspecific muscle and joint soreness
among patients in placebo-controlled trials (5%) is common,
the incidence of myalgias is similar among those receiving
placebo or active drug (Pasternak et al 2002). The incidence
of statins causing myositis (0.2%) is low (Bradford et al
1991), and even less common for fatal rhabdomyolysis (less
than 1 death/million prescriptions) (Staffa et al 2002).
Despite these reassuring statistics, practitioners should be
cognizant of potential adverse effects, especially an
increased risk of muscle toxicity among patients receiving
higher statin doses and in combination with other lipid-




Ezetimibe, a novel medication, is the most recent addition
to the class of cholesterol-lowering medications. This agent
primarily targets LDL-C and can be used as monotherapy
or as an add-on to statin therapy. Ezetimibe appears to have
an excellent safety profile with a low incidence of adverse
effects and drug interactions.
Ezetimibe inhibits the absorption of intestinal cholesterol
from dietary and biliary sources by approximately 50%
(Nutescu and Shapiro 2003), without altering the absorption
of fat-soluble vitamins, bile acids, or triglycerides (Gagne
et al 2002). This ultimately results in approximately a 20%
reduction in LDL-C with minimal changes in HDL-C or
triglycerides (Bays et al 2001). When coadministered with
a statin, ezetimibe has produced an additional 12%–25%
reduction in LDL-C (Figure 1), (Gagne et al 2002;
Ballantyne, Houri, et al 2003; Bays et al 2004; Masana et al
2005) and further reductions in high-sensitivity C-reactive
protein (CRP) (Ballantyne, Houri, et al 2003) compared with
statin monotherapy. Additional potential benefits of
ezetimibe include the reduction in intestinal uptake of plant
sterols (von Bergmann et al 2005) – a possible contributor
to atherosclerotic plaque (Miettinen et al 2005).
An advantage of ezetimibe is its safety profile, which is
similar to that of placebo (Bays et al 2001; Brown 2001;
Stein 2002). Ezetimibe is primarily metabolized in the
intestine and liver, but bypasses the cytochrome P450
system, resulting in no clinically relevant drug interactions
(Bauer et al 2001; Keung et al 2001; Kosoglou, Guillaume,
et al 2001; Kosoglou, Meyer, et al 2001; Statkevich et al
2001). Ezetimibe is available as a 10 mg tablet and also in a
combination formulation with varying simvastatin dosages
(ezetimibe 10 mg/simvastatin 10 mg–80 mg) (Bays et al
2004). All dosage forms are administered once daily.
Ezetimibe provides a needed option for patients requiring
modest monotherapy for LDL-C reduction or further
LDL-C reduction with combination therapy, and those
intolerant of other lipid-lowering drugs or at risk for drug
interactions.
The rationale for combination
therapy
Long-term statin clinical trials have demonstrated significant
reductions in cardiovascular death (22%) and total mortality
(13%) (Studer et al 2005). While impressive, the findings
also demonstrate that despite marked reductions in LDL-C,
many patients continue to experience vascular events.
Two possible strategies for further reducing events are
additional lowering of LDL-C and addressing other
abnormalities of the major lipoproteins (ie, low HDL-C,
elevated triglycerides).
ATP-III Update
The ATP-III Update was published in the summer of 2004
following the publication of five statin trials (Grundy et al
2004). This document addresses the options of both further
lowering LDL-C and targeting other lipoproteins in high-
risk persons. The report indicates that a more aggressive
LDL-C therapeutic goal of < 70 mg/dL may be appropriate
in individuals considered to be very high-risk (eg, CHD,
acute coronary syndrome [ACS], CHD-risk equivalent),
whose previous recommended LDL-C goal was < 100 mg/dL.
While some patients may be able to achieve this goal with
monotherapy, many will require adjunctive LDL-C lowering
therapy. The ATP-III Update additionally states that the
combination of a statin/fibrate or statin/niacin may be
considered for elevated triglycerides or low HDL-C in these
populations.
The Heart Protection Study
The Heart Protection Study (HPS) was a major contributor
to the body of evidence that supports the ATP-III Update. A
key point from the HPS was the finding that patients benefit
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Figure 1 Percent change from baseline in low-density lipoprotein cholesterol
(LDL-C) at study end point (12 weeks). * p < 0.001 for E/S versus same-dose S;
‡ p < 0.001 for E/S versus next highest dose of S. Adapted from Bays et al 2004.
Abbreviations: E, ezetimibe; LDL-C, low-density lipoprotein cholesterol; S,
simvastatin; SEM, standard error of the mean.Vascular Health and Risk Management 2005:1(4) 322
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from statin therapy regardless of the baseline LDL-C
(HPSCG 2002). In this trial, patients at high risk for a
cardiovascular event were randomized to simvastatin (40 mg
daily), or placebo for five years. Event reduction was similar
among those receiving statin therapy regardless of whether
the baseline LDL-C was < 100 mg/dL or > 135 mg/dL. For
individuals with baseline LDL-C levels of < 100 mg/dL,
simvastatin further reduced LDL-C to a mean level of
65 mg/dL, well below the previously recommended ATP-III
goal of < 100 mg/dL.
Pravastatin or Atorvastatin Evaluation
and Infection Therapy-Thrombolysis in
Myocardial Infarction 22 and Treating to
New Targets trials
While the HPS provided many answers, it did not address
whether larger LDL-C reductions resulted in greater event
reduction. Two major studies designed to assess this were
the Pravastatin or Atorvastatin Evaluation and Infection
Therapy-Thrombolysis in Myocardial Infarction 22
(PROVE IT-TIMI 22) and the Treating to New Targets
(TNT) trials. In the PROVE IT-TIMI 22 study, patients with
acute coronary syndrome (ACS) were randomized to
moderate (pravastatin 40 mg/day) or intensive (atorvastatin
80 mg/day) lipid-lowering therapy with a mean follow-up
of 24 months (Cannon et al 2004). The more intensive
atorvastatin therapy resulted in a significant reduction of
16% (p = 0.005) in the composite endpoint consisting of all-
cause mortality, unstable angina, stroke, myocardial
infarction (MI), and revascularization procedures compared
with pravastatin. Atorvastatin achieved a mean treatment
LDL-C of 62 mg/dL compared with 95 mg/dL with
pravastatin. These findings were further reinforced in the
TNT trial in patients with stable CHD (LaRosa et al 2005).
The TNT trial randomized patients to low (10 mg/day) or
high-dose atorvastatin (80 mg/day). A significant 22%
(p < 0.001) reduction in the composite endpoint of major
cardiovascular events was achieved with the high-dose
therapy after a median follow-up of nearly 5 years. Despite
the substantial reduction in the composite endpoint, overall
mortality was not significantly different among the treatment
groups. Mean LDL-C levels with the high-dose atorvastatin
were 77 mg/dL compared with 101 mg/dL with low-dose
therapy. This trial provides additional evidence for the
benefit of reducing LDL-C levels considerably beyond the
previous threshold of < 100 mg/dL for those with CHD.
Aggressively treating elevated triglycerides and low
HDL-C may also reduce cardiovascular events. Epidemio-
logical data indicate that every 1 mg/dL increase in HDL-C
is associated with a reduction in cardiac events of 2%–4%,
independent of LDL-C (Gordon et al 1989). Low HDL-C
remains a predictor of future events in subanalyses of statin
trials. Subjects randomized to statins with low HDL-C often
experienced higher CHD event rates compared with those
with higher HDL-C (Sacks et al 2000). Hypertriglyceridemia
is not only associated with numerous risk factors for CHD
(eg, low HDL-C, impaired fasting glucose, elevated
fibrinogen), but is considered by the ATP-III report to be an
independent risk factor for atherosclerosis (ATP-III 2002).
The Veterans Affairs HDL-C
Intervention Trial
Although the major focus for the past 10 years has been
LDL-C reduction with statins, many other trials have
produced impressive results by targeting HDL-C or
triglycerides. The Veterans Affairs HDL-C Intervention Trial
(VA-HIT) randomized men with CHD to gemfibrozil
(600 mg twice daily) or placebo for 5 years (Rubins et al
1999). Gemfibrozil was specifically chosen because of its
neutral effect on LDL-C levels. The primary lipid
abnormality among the patients was a low HDL-C, with
baseline HDL-C, LDL-C and triglycerides values of
32 mg/dL, 111 mg/dL, and 161 mg/dL, respectively.
Gemfibrozil significantly increased HDL-C by 6%
(p < 0.001) and reduced triglycerides by 31% (p < 0.001),
with no effect on LDL-C. Treatment resulted in a 22%
(p = 0.006) reduction in the composite endpoint of CHD
death and nonfatal MI. The VA-HIT was the first randomized
controlled trial utilizing lipid-altering therapy to demonstrate
a reduction in CHD events without lowering LDL-C.
Arterial Biology for the Investigation of
the Treatment Effects of Reducing
Cholesterol 2 study
The Arterial Biology for the Investigation of the Treatment
Effects of Reducing Cholesterol 2 trial evaluated the addition
of niacin to statin therapy among secondary prevention
patients with low HDL-C. Atherosclerosis progression was
measured by carotid intimamedia thickness (CIMT) (Taylor
et al 2004), a surrogate marker for cardiovascular events.
Patients already on statin therapy were randomized to ER
niacin (1000 mg/day) or placebo. Carotid intimamediaVascular Health and Risk Management 2005:1(4) 323
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thickness was measured at baseline and 12 months. The
primary change in the lipid profile with ER niacin was a
21% increase in HDL-C (p = 0.003). Patients in the placebo
arm showed a significant increase in CIMT after 12 months
(0.044 mm ± 0.100 mm; p < 0.001) while the niacin group
experienced no change (0.014 mm ± 0.104 mm; p = 0.23).
The authors concluded that the addition of niacin to statin
therapy among patients with low HDL-C and CHD slowed
the progression of atherosclerosis.
HDL-C-Atherosclerosis Treatment
Study
A small trial designed to evaluate the benefits of significantly
improving HDL-C and LDL-C was the HDL-C-Athero-
sclerosis Treatment Study (HATS) (Brown et al 2001).
Patients with a previous history of CHD and low HDL-C
(n = 160) were randomized to a combination of simvastatin
and niacin or placebo for three years. The treatment group
experienced marked changes in HDL-C (+26%, p < 0.001)
and LDL-C (–42%, p < 0.001) and also demonstrated
significant angiographic regression (–0.4%, p < 0.001) from
baseline. Compared with placebo, those receiving
simvastatin and niacin experienced a 90% reduction
(p = 0.03) in clinical events (ie, CHD death, MI, stroke,
revascularization procedure, worsening ischemic symptoms).
Additional randomized controlled trials with more subjects
are required to confirm these findings.
No large trials have adequately evaluated the clinical
outcomes of combined statin and fibrate therapy. The Lipids
in Diabetes Study (LDS) using a cerivastatin and fenofibrate
regimen was halted early because of the cerivastatin withdrawal.
The Action to Control Cardiovascular Risk in Diabetes trial
(ACCORD), sponsored by the National Institute of Health
(NIH), will evaluate clinical outcomes with this combination.
Subjects with a previous history of DM will be randomized to
statin monotherapy or combined statin/fibrate therapy. The
ACCORD trial, expected to be completed in 2009, should
provide valuable long-term safety information on
combination therapy and determine whether the addition of
a fibrate provides further reduction in clinical events.
A major health concern worldwide is the increasing
prevalence of the metabolic syndrome and DM (ATP-III
2002; Wild et al 2004). The typical lipid pattern among these
populations is mixed dyslipidemia with a predominance of
the more atherogenic sdLDL-C. Angiographic studies have
demonstrated sdLDL-C to be a key factor in atherosclerotic
progression (Watts et al 1993; Haskell et al 1994) as well as
increasing CHD risk by up to sevenfold (Griffin et al 1994;
Lamarche et al 1997). In order to meet all lipoprotein goals
(ie, LDL-C, HDL-C, triglycerides) and normalize LDL-C
distribution among these high-risk populations, the
combined use of lipid-altering agents will likely be required.
In summary, the results from recent statin trials suggest
that high-risk patients benefit from statin therapy regardless
of baseline LDL-C, and that greater LDL-C reductions for
those with CHD appear to further reduce cardiovascular
events. Studies evaluating long-term outcomes from
combination therapy are limited, however, smaller studies
and epidemiological findings suggest substantial benefit.
The results of these studies will likely increase the use of
higher statin doses and also combination therapy to achieve
greater LDL-C reductions and improvements in elevated
triglycerides, low HDL-C, and LDL-C distribution.
Choosing the optimal regimen
Substantial changes in lipoproteins are seen when combining
lipid-altering agents (Table 1). Interpretation is limited,
however, because the data are derived from multiple studies
using different statins with varying degrees of potency.
A controversy in the lipid community is whether to
increase the dose of a statin or add adjunctive therapy for
further LDL-C reduction. Proponents of increasing the statin
dose argue that keeping the regimen simple will improve
adherence, be more cost-effective, and that adjunctive agents
may not provide additional pleiotropic effects (eg, CRP
reduction) comparable to higher statin doses. Conversely,
others argue that doubling the statin dose may result in only
a 6% further reduction in LDL-C with increased side effect
potential, whereas the addition of ezetimibe or a BAS may
result in approximately a 20% reduction in LDL-C. In reality
each side of the controversy has valid points. While
increasing the statin dose may be the simplest option in
certain cases, statins do have dose-dependent side effects
particularly when titrated to the highest doses. For example,
the incidence rates of myopathy and elevated transaminases
increase by approximately 4–5 fold when titrating
simvastatin or atorvastatin from 40 mg to 80 mg daily
(Davidson 2002). In cases such as this, adding a second
agent (ie, ezetimibe, colesevelam) with a different site of
action will not only provide more LDL-C reduction but also
limit potential side effects.
The use of fixed combination lipid-altering products (ie,
ezetimibe/simvastatin and lovastatin/ER niacin) offers
potential advantages, and in certain cases, may beVascular Health and Risk Management 2005:1(4) 324
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preferential to adding a separate second agent or titrating
the statin. The attributes of these products compared with
statin monotherapy include an overall improved effect on
the lipid profile and the possibility of greater cost-
effectiveness. These advantages may be especially true
when targeting LDL-C with the ezetimibe/simvastatin
combination. Numerous studies have demonstrated
additional LDL-C reduction when ezetimibe is added to
statin therapy (Gagne et al 2002; Melani et al 2003;
Ballantyne, Houri, et al 2003; Ballantyne et al 2005; Masana
et al 2005). Ballantyne et al (2005) conducted a dose-
comparison study of the ezetimibe/simvastatin combination
to atorvastatin among 1902 hypercholesterolemic patients.
During this 6-week, multicenter, double-blind, parallel-
group study, patients not at their ATP-III LDL-C goal were
randomized to atorvastatin (10 mg, 20 mg, 40 mg, or 80 mg)
or to ezetimibe/simvastatin (10/10 mg, 10/20 mg, 10/40 mg,
or 10/80 mg). Ezetimibe/simvastatin therapy resulted in
greater reductions compared with atorvastatin when
evaluating LDL-C reduction with mean changes across all
doses (Table 2). Additionally, ezetimibe/simvastatin
produced a significantly greater increase in HDL-C levels
and comparable reductions in triglycerides and CRP
compared with atorvastatin.
There is less controversy surrounding additional agents
for other types of dyslipidemia. Among patients with low
HDL-C, attaining the LDL-C goal is the first priority
followed by achieving the non-HDL-C goal and maximizing
therapeutic lifestyle changes. If HDL-C still remains a
concern, therapy with niacin or fibrates may then be
considered (ATP-III 2002). Although side effects can limit
niacin use, only moderate doses (1000 mg/day) are required
to significantly raise HDL-C (24%) while minimizing
adverse events, when added to a statin (Wolfe et al 2001). If
patients have mixed dyslipidemia, and triglycerides exceed
500 mg/dL, the first objective is to reduce the triglycerides
in order to prevent pancreatitis (ATP-III 2002). Many
practitioners prefer fibrates for hypertriglyceridemia because
of the greater effectiveness, lower incidence of side effects,
and lesser need for titration compared with niacin. These
individuals may require a statin for LDL-C reduction after
the triglycerides are reduced. Additional precautions must
be taken with this combination to avoid possible adverse
events (see next section).
Table 2 Summary of efficacy results in the modified intention-to-treat population  (% change from baseline)
Atorva EZ/Simva Atorva EZ/Simva Atorva EZ/Simva Atorva EZ/Simva All All
10 mg 10/10 mg 20 mg 10/20 mg 40 mg 10/40 mg 80 mg 10/80 mg  Atorva  EZ/Simva











* –32.1 –30.8 –25.5 –27.4
*
TG –21.3 –25.5 –24.8 –25.4 –23.6 –27.3 –32.1 –30.8 –25.5 –27.4
* p < 0.001 for between-treatment difference with same dose of atorvastatin. Adapted from Ballantyne et al 2005
Abbreviations: Atorva, atorvastatin; EZ/Simva, ezetimibe/simvastatin; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TC,
total cholesterol; TG, triglycerides
Table 1 Mean lipoprotein changes of various lipid-altering regimens
% Change from baseline
Regimen TC LDL-C HDL-C TG
Statin
a –15 to –40 –20 to –55 +2 to +10 –7 to –28
Statin + BASb –29 to –40 –42 to –56 +4 to +18 –12 to +19
Statin + Niacin
c –23 to –31 –29 to –45 +26 to +41 –30 to –42
Statin + Fibrate
d –26 to –37 –24 to –50 +14 to +34 –32 to –57
Statin + Ezetimibee –25 to –49 –39 to –60 +5 to +9 –18 to –40
Statin + BAS + Niacin
f –56 –57 to –66 +27 to +32 –45
a Jones et al 2003
b Malloy et al 1987, Brown et al 1990, Pan et al 1990, Gaw et al 1996, Brown et al 1998, Knapp et al 2001
c Stein et al 1996, Guyton et al 1998, Brown et al 2001, Kashyap et al 2002
d Athyros et al 1997, Athyros et al 2002, Liamis et al 2002, Derosa et al 2004
e Ballantyne, Houri, et al 2003, Melani et al 2003, Ballantyne et al 2005
f Malloy et al 1987, Brown et al 1997
Abbreviations: TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, triglycerides; BAS, bile acid
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Problems and pitfalls
The potential for increased adverse events must be
considered with the use of more aggressive lipid-altering
therapy, including higher statin doses and combination
therapy. The risk of additional serious adverse events appears
to be extremely low when using agents with excellent safety
profiles (ie, cholesterol absorption inhibitor, BAS) in
combination with statins (McKenney 2002). However, cases
of rhabdomyolysis with ezetimibe alone (Merck/Schering-
Plough 2005) or in combination with other agents associated
with muscle toxicity (eg, statins) have been reported (Fux
et al 2004). Additionally, fibrate monotherapy is associated
with a risk for muscle toxicity similar to that of statin
monotherapy (Pasternak et al 2002). As a result, concerns
regarding an increased incidence of adverse effects are valid
and must be monitored appropriately when using statins in
combination with other agents (ie, ezetimibe, fibrates,
niacin).
Myopathy
Cerivastatin was voluntarily withdrawn from the market in
August 2001 because of 31 deaths related to severe
rhabdomyolysis (Pasternak et al 2002). Staffa et al (2002)
reported fatal rhabdomyolysis to be 16–80 times more
frequent with cerivastatin compared with other statins. Later
reports from the manufacturer (Bayer AG) indicated that as
many as 100 deaths were related to the use of cerivastatin.
Twelve of the original cases involved concomitant therapy
with the fibrate gemfibrozil. Pharmacokinetic studies
evaluating gemfibrozil administered with various statins
revealed an increase in serum concentrations of all statins
studied, (ie, cerivastatin, pravastatin, rosuvastatin, simvastatin)
except fluvastatin (Spence et al 1995; Backman et al 2000,
2002; Pan et al 2000; Kyrklund et al 2001; Davidson 2002;
Martin et al 2003; Bergman et al 2004). A recent publication
utilizing reports from the FDA from January 1998 to March
2002 showed that the combined use of gemfibrozil and a
statin resulted in 590 cases of rhabdomyolysis compared
with 16 with fenofibrate and statin therapy (Jones and
Davidson 2005). The majority of cases with both gemfibrozil
(533) and fenofibrate (14) also involved cerivastatin. When
considering the number of prescriptions dispensed during
that timeframe, this indicates an approximate 20-fold
increase with the gemfibrozil/statin regimen compared with
the fenofibrate/statin combination. It should be noted that
these findings represent only reported event rates rather than
the actual incidence rates. The findings nevertheless strongly
suggest a greater rate of rhabdomyolysis with cerivastatin
and also the combined use of statin therapy with gemfibrozil.
When combining a statin with niacin the risk for myopathy
appears to be the same as statin monotherapy (Davidson
2002). No clinically significant drug interactions exist
between niacin and statins, and case reports of myopathy
involving both agents are extremely limited.
The above information clearly points out the risks,
particularly of myopathy, that can be associated with
combination therapy. However, the risk of severe myopathy
can be greatly reduced if appropriate measures are taken.
The American College of Cardiology along with the
American Heart Association and the National Heart, Lung
and Blood Institute published a clinical advisory shortly after
the cerivastatin withdrawal, identifying concomitant
medications that may predispose patients to statin-induced
myopathy (Table 3).
Hepatotoxicity
The most serious adverse event that occurs with niacin is
hepatotoxicity. The frequency is dependent on the dose and
formulation utilized. Serious liver toxicity has been reported
with the SR formulation in up to 50% of patients receiving
≥ 2000 mg/day (McKenney et al 1994). The incidence with
the IR (3%) (Guyton et al 1998) and ER (1%) (Kashyap et
al 2000) formulations is much lower and appears not to be
increased with the addition of a statin. Fibrate monotherapy
has also been associated with abnormalities in liver function
and while it is likely that the incidence is higher with
combined statin therapy, data are limited.
Patient focus
Nonadherence
Despite ample evidence from numerous clinical trials and
meta-analyses demonstrating that lipid-lowering therapy can
Table 3 Agents increasing risk for statin-associated myopathy










Adapted from Pasternak et al 2002
Abbreviations: HIV, human immunodeficiency virus.Vascular Health and Risk Management 2005:1(4) 326
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reduce cardiovascular morbidity and mortality (Anonymous
1984; Frick et al 1987; Anonymous 1994; Holme 1995;
Furberg 1994; HPSCG 2002; Shepherd et al 2002; Sever et
al 2003; Cannon et al 2004), adherence to prescribed therapy
is generally poor. For example, in a 5-year, double-blind
trial of 4081 dyslipidemic middle-aged men, researchers
found that only 36% of men in the active treatment group
(gemfibrozil) took more than 90% of the prescribed dose,
and adherence declined over time (Maenpaa et al 1992).
Long-term compliance is essential because maximal
reductions in cardiovascular disease may require 1.5 years
of continuous therapy or more (Anonymous 1994; Sacks
2000). However, in the West of Scotland Study, the
cumulative rates of withdrawal from pravastatin were 14.9%
during the first year and 29.6% at year five (Shepherd et al
1995). While surveys in clinical settings often report that
many patients fail to achieve target lipid levels (Pearson
2000; Pearson et al 2000), a very recent study indicates the
frequency of achieving lipid goals is improving (Davidson
et al 2005).
As outlined by LaRosa and LaRosa (2000), patient
noncompliance can be manifested in many ways including
outright refusal, taking incorrect doses, forgetting or
skipping doses for several days, compliance only before
physician visits, and prescriber concern with utilizing the
highest statin doses. Various reasons cited for noncompliance
include lipid-lowering benefits not compelling enough to
change behavior (Horne and Weinman 1999), fear or
intolerance of adverse effects, and management difficulties
associated with multidrug regimens (Luepker 1993). Other
social, cultural, and economic factors reported to be
significantly associated with poorer compliance with lipid-
lowering medications include unmarried status, gender, lack
of insurance, depression, disease state, lack of knowledge
about the disease process, cost, and patient–physician
relationship (Insull 1997; Maviglia et al 2001; Kaplan et al
2004). Convincing patients of the benefits of primary
prevention may be more difficult than secondary prevention
because patients are typically asymptomatic and potential
harmful effects may be perceived as being far in the future.
Enhancing adherence
For many dyslipidemic patients who cannot achieve LDL-C
goals with monotherapy, combination drug therapy has been
recommended (Davidson and Toth 2004). Strategies to
enhance compliance with lipid-lowering combination
therapy can be gained from a recently published study
among patients with hypertension and dyslipidemia.
Investigators examined the patterns and predictors of
adherence with concomitant therapy among 8406 enrollees
in a managed-care organization who had been prescribed
both antihypertensive (AH) and lipid-lowering (LL)
medications within a period of 90 days (Chapman et al
2005). Adherence to both medications declined sharply
throughout the study to less than half of patients at 3 months,
and one-third at 6 months. After adjustment for age, gender,
and other potential predictors, investigators found that
patients were more likely to be adherent if they initiated
AH and LL therapy on or about the same date, had a history
of CHD or congestive heart failure, or took fewer additional
medications. The authors suggested that physicians might
be able to significantly improve adherence by initiating
combination therapy concomitantly and reducing the pill
burden. Similarly, ATP-III guidelines recommend simplify-
ing medication regimens, stating that patients are more likely
to take once-daily medications and regimens with fewer total
drugs.
Several strategies that have been shown to increase
patient compliance can be achieved with the use of once
daily combination drug products such as ezetimibe/
simvastatin (Vytorin) and lovastatin/ER niacin (Advicor).
In a recent study, ezetimbe/simvastatin was shown to be a
highly efficacious treatment option for hypercholesterolemic
patients. The combination was more effective than
atorvastatin in lowering LDL-C and provided greater
increases in HDL-C at higher dosages (Ballantyne et al
2005). Patient fears about possible adverse effects may be
lessened by the finding that the product was well tolerated
with a low incidence of adverse effects. Similarly, the
lovastatin and ER niacin combination product effectively
reduces TC, LDL-C, triglycerides, apo B, Lp(a), increases
HDL-C, and has a low incidence of flushing, myopathies,
and hepatotoxicity (Gupta and Ito 2002; Moon and Kashyap
2002; Bays et al 2003). With this product, however, the
perceived intolerance of niacin may be a barrier to use.
In addition to patient barriers, poor physician compliance
with published guidelines (ie, identifying eligible patients,
initiating appropriate treatment regimens, and achieving
optimal treatment goals) is well documented. For example,
data from the National Registry for Myocardial Infarction
indicated that only one third of patients discharged from
hospital after an acute MI were placed on lipid-lowering
therapy (Fonarow et al 2001). Similarly, a study to determine
the effectiveness of current lipid management practices inVascular Health and Risk Management 2005:1(4) 327
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patients admitted for peripheral vascular surgery found that
only a minority achieved the recommended NCEP goal
(Cote et al 2003).
Other significant contributors to the treatment gap
include prescribing lipid-lowering therapy at insufficient
doses or using drugs with limited effectiveness. Several
options for improving lipid management include dose
titration, initiating treatment with a higher starting dose
(Isaacsohn et al 2003), combination therapy, or prescribing
a more efficacious statin (Schuster 2004). Yet, numerous
studies have demonstrated that physicians are reluctant to
modify or titrate the initially chosen therapy, citing
tolerability concerns and possible risks of adverse effects.
In the Simvastatin Treats Asians to Target (STATT) study, a
multicenter, open label trial in patients with CHD and serum
LDL-C levels of 115 mg/dL–180 mg/dL and triglycerides
levels of ≤ 400 mg/dL, investigators employed a titrate-to-
goal protocol to evaluate the efficacy and tolerability of
simvastatin (Chung et al 2001). The dose of simvastatin was
titrated from 20 mg/dL to 80 mg/dL to achieve the NCEP
LDL-C target of ≤ 100 mg/dL. Overall, titration enabled the
majority of these patients to achieve target LDL-C levels of
≤ 100 mg/dL and simvastatin was well tolerated across the
dose range with no reports of serious adverse effects.
A number of different strategies have been employed to
improve physician compliance with NCEP ATP-III
guidelines. For example, automatic prescriptions, whereby
physicians allow another team member to change lipid-
lowering medications (eg, medical director or pharmacist)
(Siskind et al 2000) and microelectronic devices which
provide adherence feedback to patients (Schwed et al 1999)
have been shown to help physicians comply with NCEP
guidelines and possibly increase long-term adherence.
Additionally, utilizing physician extenders, such as nurses
(DeBusk et al 1994) and pharmacists, (Konzem et al 1997;
Bluml et al 2000; Faulkner et al 2000) is associated with
increased compliance and achievement of lipid goals.
Similarly, ATP-III guidelines advocate the use of case
management by nurses and the collaborative care of
pharmacists as possible strategies that focus on the health
delivery system to improve adherence (ATP-III 2002).
In summary, many patients are not achieving LDL-C
levels recommended by NCEP ATP-III guidelines. Several
strategies that target patients, providers, and health delivery
systems are available to help more patients achieve
recommended lipid levels and prevent the development or
progression of cardiovascular disease.
Conclusion
The use of combination lipid-altering therapy is becoming
more commonplace and will likely continue to increase over
time. The recent publication of the ATP-III Update supports
the use of combination therapy in high-risk individuals for
achieving lipoprotein goals, especially LDL-C reduction.
While more aggressive treatment with combination therapy
is relatively safe, the potential for adverse events increases
and additional monitoring and patient education is crucial.
Issues of noncompliance with cholesterol drugs continue
to be problematic. Focusing on methods to improve patient
adherence, including the use of fixed combinations, will be
essential to achieve the maximum benefits from these agents.
Finally, the completion of ongoing trials evaluating
combination therapy should provide valuable additional
evidence on the potential benefits of this emerging treatment
strategy.
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